Multi-Chimeric Cell Fusion for Broader Stem Cell Graft Matching
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The limitations of allogeneic stem cell grafts due to the lack of matched donors and the high mortality and morbidity from conditioning regimens and graft-versus-host-disease (GvHD) in hematopoietic stem cell transplantation hinder its application as a treatment for many diseases.
Innovation Solution
Development of a multi-chimeric cell fusion product comprising hematopoietic stem cells and other cell types from multiple donors, which are fused ex vivo using fusogenic agents, allowing for enhanced engraftment and reduced GvHD risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If allogeneic stem cell grafts are used for transplantation, then the treatment options for hematological diseases are expanded, but the mortality and morbidity increase due to conditioning regimens and graft-versus-host-disease
Solution Approach 1:
The patent merges stem cells from multiple donors (at least two different donors) into a single multi-chimeric cell product. This combination allows the graft to express multiple HLA types simultaneously, expanding treatment options for patients with limited donor matches while the balanced composition reduces the risk of GvHD and improves transplantation safety
Solution Approach 2:
The multi-chimeric cell product functions as a composite biological material combining genetic and immunological properties from multiple donors. This composite structure enables the graft to provide both broad HLA matching capability (improving adaptability) and balanced immune recognition (reducing harmful GvHD responses, thereby improving reliability)
2Adaptability or versatility
If matched unrelated HSC transplants are performed, then the availability of stem cell grafts is improved, but the toxicity from conditioning regimens and GvHD increases
Solution Approach 1:
By combining stem cells from multiple donors into a multi-chimeric product, the invention expands the availability of matched grafts while the distributed HLA expression across multiple cell lineages balances the immune response, reducing the severity of GvHD and conditioning regimen toxicity
Solution Approach 2:
The invention changes the immunological parameters of the graft by creating a multi-chimeric product with combined HLA profiles. This parameter change allows better matching with diverse patients (improving availability) while the composite HLA expression pattern modifies the immune interaction to reduce toxicity and GvHD severity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multi-chimeric cell therapy improves engraftment rates and reduces the severity of GvHD, providing a more effective treatment for immune deficiencies and genetic disorders without the need for lifelong immunosuppression.
Implementation Method 1
multi-chimeric cell fusion product comprising (a) a hematopoietic stem cell and (b) two or more cells independently selected from hematopoietic stem cells, mesenchymal stem cells, myoblasts, satellite cells and pericytes, wherein the cells of (a) and (b) are isolated and purified from three or more different donors
Data Source
Figure 1
AI summary
A multi-chimeric cell created by ex vivo fusion of three or more hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, or satellite cells, or a combination thereof, from three or more different donors is provided, as is the use of these cells in thransplant therapy and treatment of immune deficiency and genetic disorders.